Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review

Abstract

Background Campylobacter spp. cause mostly self-limiting enterocolitis, although a significant proportion of cases require hospitalisation highlighting potential for severe disease. Among people admitted, blood culture specimens are frequently collected and antibiotic treatment is initiated. We sought to understand clinical and host factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations. Methods Using linked hospital microbiology and administrative data we identified and reviewed Campylobacter-associated hospitalisations between 2004 and 2013. We calculated population-level incidence for Campylobacter bacteraemia and used logistic regression to examine factors associated with bacteraemia, antibiotic treatment and isolate non-susceptibility among Campylobacter-associated hospitalisations. Results Among 685 Campylobacter-associated hospitalisations, we identified 25 admissions for bacteraemia, an estimated incidence of 0.71 cases per 100,000 population per year. Around half of hospitalisations (333/685) had blood culturing performed. Factors associated with bacteraemia included underlying liver disease (aOR 48.89, 95% CI 7.03–340.22, p < 0.001), Haematology unit admission (aOR 14.67, 95% CI 2.99–72.07, p = 0.001) and age 70–79 years (aOR 4.93, 95% CI 1.57–15.49). Approximately one-third (219/685) of admissions received antibiotics with treatment rates increasing significantly over time (p < 0.05). Factors associated with antibiotic treatment included Gastroenterology unit admission (aOR 3.75, 95% CI 1.95–7.20, p < 0.001), having blood cultures taken (aOR 2.76, 95% CI 1.79–4.26, p < 0.001) and age 40–49 years (aOR 2.34, 95% CI 1.14–4.79, p = 0.02). Non-susceptibility of isolates to standard antimicrobials increased significantly over time (p = 0.01) and was associated with overseas travel (aOR 11.80 95% CI 3.18–43.83, p < 0.001) and negatively associated with tachycardia (aOR 0.48, 95%CI 0.26–0.88, p = 0.02), suggesting a healthy traveller effect. Conclusions Campylobacter infections result in considerable hospital burden. Among those admitted to hospital, an interplay of factors involving clinical presentation, presence of underlying comorbidities, complications and increasing age influence how a case is investigated and managed.

Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021

“…The leading cause was malignancy or cancer (33%) ( 1 , 20 ). Two patients with documented C. fetus bacteremia had systemic sclerosis, which seems to be a predisposing condition among connective tissue diseases ( 1 , 21 ). Pacanowski et al ( 5 ) showed that, compared with patients with bacteremia caused by other Campylobacter species, patients with C. fetus bacteremia were older and had underlying comorbidities (e.g., cardiovascular diseases, diabetes mellitus).…”

A South African Perspective on the Microbiological and Chemical Quality of Meat: Plausible Public Health Implications

“…Most cases of campylobacteriosis are sporadic and self-limiting, hence, antimicrobial treatment becomes unnecessary. However, when the case needs hospitalisation, indicating potentially severe disease, antibiotics, including ciprofloxacin, azithromycin, erythromycin, and tetracyclines, are administered [115,116]. Nevertheless, cephalosporins should be avoided due to high resistance rates [103].…”

Structural basis of DNA recognition of the Campylobacter jejuni CosR regulator

“…Enteritis is the prime clinical indicator of campylobacteriosis ( 3 ), which may include hematochezia, diarrhea, cramping, abdominal pain, fever, nausea, and vomiting. Extraintestinal infections such as bacteremia ( 4 , 5 ), hepatitis ( 6 ), and pancreatitis ( 7 ) may also occur. In addition, some infected patients may develop postinfection complications, including reactive arthritis ( 8 ) and neurological disorders such as Guillain-Barré syndrome ( 2 ).…”